FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310104966> ?p ?o ?g. }

• W4310104966 endingPage "9073" @default.
• W4310104966 startingPage "9070" @default.
• W4310104966 abstract "Background: SNDX-5613 is a potent, orally available, small molecule inhibitor of menin, which binds to MLL1, encoded by the KMT2A gene, and MLL1 fusion proteins. Menin expression leads to aberrant gene transcription through its activation of Homeobox-related genes, leading to maturation arrest and leukemogenesis in KMT2A-rearranged and NPM1-mutated leukemias. Inhibition of menin activity significantly blocks the transcriptional signature and subsequently the proliferative capacity of leukemia cells harboring NPM1 mutations or KMT2A rearrangements. SNDX-5613 and its analogs have demonstrated robust single-agent anti-proliferative activity in NPM1-mutated AML cells and AML patient-derived xenograft models. Currently, SNDX-5613 is being explored as a single agent in a phase 1/2 study in patients with NPM1-mutated or KMT2A-rearranged relapsed/refractory AML, mixed phenotypic acute leukemia and acute lymphoblastic leukemia. The primary objective of this study is to determine the safety and recommended dose of SNDX-5613 combined with AZA and VEN in untreated AML patients age ≥ 60 years who are not candidates for intensive chemotherapy. Study Design and Methods: This study is a sub-study of the BeatAML Master Trial (NCT03013998) in which untreated AML patients age ≥ 60 are assigned an investigational therapy based on cytogenetic and central genomic analysis. Patients must specifically harbor an identifiable NPM1 mutation without a concomitant FLT3 mutation or have a KMT2A rearrangement to be eligible. In this phase 1b study, the primary objective is to determine the safety and recommended dose using a standard 3+3 design based on dose-limiting toxicities with 3 dose levels (DL) of SNDX-5613 to be evaluated in combination with VEN/AZA and an anti-fungal (required during induction): 75mg (DL-1), 113mg (DL1), and 163mg (DL2). In continuation phase with anti-fungals not required, SNDX-5613 will be dosed at 113mg (DL-1), 163mg (DL1), or 226mg (DL2) with appropriate dose reductions added for both SNDX-5613 and VEN if continuing on anti-fungals. The secondary objectives are to assess the overall response rate, measurable residual disease (MRD) status, overall survival, transplant rate and duration of remission. During induction cycles, VEN (D1-28) and AZA (D1-7) are dosed per standard of care every cycle. SNDX-5613 is dosed continuously orally twice daily with dose levels listed above. In patients who achieve a morphologic remission (<5% blasts), SNDX-5613 will be held if absolute neutrophil count (ANC) is < 0.5x109/L and/or platelets (PLT) < 50x109/L. Patients can receive up to 3 induction cycles to achieve a composite complete remission (CRc: CR, CRi, CRh). Patients can receive continuation therapy with AZA, VEN and SNDX-5613 once they achieve CRc and after hematologic recovery. Following the determination of a safe and recommended dose in phase 1b, there will be a dose expansion cohort of 12-20 patients following the same schedule as described above (Figure 1) to further evaluate safety, tolerability and correlative biomarkers. Correlative objectives include assessment of SNDX-5613 pharmacokinetics and its correlation with response and toxicities. Additionally, the study will evaluate the impact of MRD, as measured by central flow cytometry and next-generation sequencing of NPM1 mutations. Additional evaluations and biomarkers of potential interest include menin- KMT2A-specific transcriptomic changes, myeloid differentiation/cell subset changes, mechanisms of resistance, and discovery of baseline features (methylation, mutations, etc.) that can impact outcomes. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal" @default.
• W4310104966 created "2022-11-30" @default.
• W4310104966 creator A5003453954 @default.
• W4310104966 creator A5004524654 @default.
• W4310104966 creator A5005939966 @default.
• W4310104966 creator A5013231204 @default.
• W4310104966 creator A5013411479 @default.
• W4310104966 creator A5021059238 @default.
• W4310104966 creator A5023917898 @default.
• W4310104966 creator A5025660159 @default.
• W4310104966 creator A5025932247 @default.
• W4310104966 creator A5028131338 @default.
• W4310104966 creator A5031561153 @default.
• W4310104966 creator A5032988049 @default.
• W4310104966 creator A5033023115 @default.
• W4310104966 creator A5033236261 @default.
• W4310104966 creator A5035051206 @default.
• W4310104966 creator A5035236340 @default.
• W4310104966 creator A5037299848 @default.
• W4310104966 creator A5038913208 @default.
• W4310104966 creator A5040205668 @default.
• W4310104966 creator A5040303721 @default.
• W4310104966 creator A5049910941 @default.
• W4310104966 creator A5053574319 @default.
• W4310104966 creator A5062338109 @default.
• W4310104966 creator A5065914027 @default.
• W4310104966 creator A5066934816 @default.
• W4310104966 creator A5068817380 @default.
• W4310104966 creator A5068908740 @default.
• W4310104966 creator A5069774776 @default.
• W4310104966 creator A5076825184 @default.
• W4310104966 creator A5079400267 @default.
• W4310104966 creator A5090729996 @default.
• W4310104966 creator A5090985347 @default.
• W4310104966 date "2022-11-15" @default.
• W4310104966 modified "2023-10-18" @default.
• W4310104966 title "A Phase 1b Dose Escalation and Expansion Study of SNDX-5613, Azacitidine (AZA) and Venetoclax (VEN) in Newly Diagnosed, Patients ≥ 60 Years with Untreated <i>NPM1</i>-Mutated/ <i>FLT3</i>-Wild Type AML or <i>KMT2A</i>-Rearranged Acute Myeloid Leukemia (AML)" @default.
• W4310104966 doi "https://doi.org/10.1182/blood-2022-166715" @default.
• W4310104966 hasPublicationYear "2022" @default.
• W4310104966 type Work @default.
• W4310104966 citedByCount "1" @default.
• W4310104966 countsByYear W43101049662023 @default.
• W4310104966 crossrefType "journal-article" @default.
• W4310104966 hasAuthorship W4310104966A5003453954 @default.
• W4310104966 hasAuthorship W4310104966A5004524654 @default.
• W4310104966 hasAuthorship W4310104966A5005939966 @default.
• W4310104966 hasAuthorship W4310104966A5013231204 @default.
• W4310104966 hasAuthorship W4310104966A5013411479 @default.
• W4310104966 hasAuthorship W4310104966A5021059238 @default.
• W4310104966 hasAuthorship W4310104966A5023917898 @default.
• W4310104966 hasAuthorship W4310104966A5025660159 @default.
• W4310104966 hasAuthorship W4310104966A5025932247 @default.
• W4310104966 hasAuthorship W4310104966A5028131338 @default.
• W4310104966 hasAuthorship W4310104966A5031561153 @default.
• W4310104966 hasAuthorship W4310104966A5032988049 @default.
• W4310104966 hasAuthorship W4310104966A5033023115 @default.
• W4310104966 hasAuthorship W4310104966A5033236261 @default.
• W4310104966 hasAuthorship W4310104966A5035051206 @default.
• W4310104966 hasAuthorship W4310104966A5035236340 @default.
• W4310104966 hasAuthorship W4310104966A5037299848 @default.
• W4310104966 hasAuthorship W4310104966A5038913208 @default.
• W4310104966 hasAuthorship W4310104966A5040205668 @default.
• W4310104966 hasAuthorship W4310104966A5040303721 @default.
• W4310104966 hasAuthorship W4310104966A5049910941 @default.
• W4310104966 hasAuthorship W4310104966A5053574319 @default.
• W4310104966 hasAuthorship W4310104966A5062338109 @default.
• W4310104966 hasAuthorship W4310104966A5065914027 @default.
• W4310104966 hasAuthorship W4310104966A5066934816 @default.
• W4310104966 hasAuthorship W4310104966A5068817380 @default.
• W4310104966 hasAuthorship W4310104966A5068908740 @default.
• W4310104966 hasAuthorship W4310104966A5069774776 @default.
• W4310104966 hasAuthorship W4310104966A5076825184 @default.
• W4310104966 hasAuthorship W4310104966A5079400267 @default.
• W4310104966 hasAuthorship W4310104966A5090729996 @default.
• W4310104966 hasAuthorship W4310104966A5090985347 @default.
• W4310104966 hasBestOaLocation W43101049661 @default.
• W4310104966 hasConcept C104317684 @default.
• W4310104966 hasConcept C126322002 @default.
• W4310104966 hasConcept C143998085 @default.
• W4310104966 hasConcept C150194340 @default.
• W4310104966 hasConcept C190727270 @default.
• W4310104966 hasConcept C2483381 @default.
• W4310104966 hasConcept C2776239401 @default.
• W4310104966 hasConcept C2777938653 @default.
• W4310104966 hasConcept C2778461978 @default.
• W4310104966 hasConcept C2779675984 @default.
• W4310104966 hasConcept C30481170 @default.
• W4310104966 hasConcept C38652104 @default.
• W4310104966 hasConcept C41008148 @default.
• W4310104966 hasConcept C53226629 @default.
• W4310104966 hasConcept C54355233 @default.
• W4310104966 hasConcept C71924100 @default.
• W4310104966 hasConcept C86803240 @default.
• W4310104966 hasConcept C9583187 @default.
• W4310104966 hasConceptScore W4310104966C104317684 @default.
• W4310104966 hasConceptScore W4310104966C126322002 @default.
• W4310104966 hasConceptScore W4310104966C143998085 @default.
• W4310104966 hasConceptScore W4310104966C150194340 @default.

• next